Avant Technologies, Inc. (OTCQB: AVAI) and its joint venture partner, Ainnova Tech, Inc., are in discussions with an international healthcare innovation company to license or potentially acquire its patented early disease detection technology. This move aims to create a more accessible, low-cost approach to preventive health reporting and disease prediction, leveraging artificial intelligence (AI).

Vinicio Vargas, CEO of Ainnova, emphasized the company’s mission to make early disease detection available everywhere, at a low cost, and with ease. ‘Our purpose is to create the future of early disease detection in an accessible way, so that patients can get a preventive check-up anywhere, at a low cost, and easily,’ he stated. ‘We want to prevent patients with risk factors from developing other diseases that could have been avoided before they became a real problem.’

Both companies are working to expand their technology portfolio with the goal of leading in AI-driven early detection. They have already integrated four algorithms into their Vision AI platform, which focuses on comprehensive health reports by leveraging the retina as a vital sign, along with other laboratory and patient data.

Vargas highlighted that they are in negotiations to license or acquire an innovative technology that could be a game changer in the health industry. ‘We are seeking to integrate new technologies into our platform within a single, accessible solution,’ he explained. ‘Our vision is to revolutionize preventive health reporting and provide early detection of diseases without the need for extensive patient data.’

Additional details about the companies and their efforts to enhance healthcare through AI can be found on their respective websites. Avant Technologies and Ainnova are committed to advancing healthtech solutions that aim to improve early diagnosis and disease prevention.’

As they move forward, the companies plan to keep their shareholders informed about any developments.